← All trials
NCT01141023
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2010
- Primary completion
- Sep 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 680
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Michael J. Fox Foundation for Parkinson's ResearchLead sponsor
- Institute for Neurodegenerative DisordersStudy chair
- University of PennsylvaniaOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- Institute for Neurodegenerative DisordersOverall official - principal investigator
- Coriell Institute for Medical ResearchOverall official - principal investigator
- University of IowaOverall official - principal investigator
- Michael J. Fox Foundation for Parkinson's ResearchSponsor investigator
- Institute for Neurodegenerative DisordersCollaborator
- National Institutes of Health (NIH)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.